X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combination also demonstrated the activation, mobilization, and proliferation of CD8 T cells and NKs, with slightly more modest effects on granulocytes, in most patients at lower ICT01 doses than shown in previously presented data of ICT01 monotherapy in a similar patient.
Lead Product(s): ICT01,Aldesleukin
Therapeutic Area: Oncology Product Name: ICT01
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
Broad antitumor immune responses and demonstration of durable disease control from solid tumor patients who previously failed one or more checkpoint-inhibitor regimen, across a range of ICT01 doses in combination with pembrolizumab.
Lead Product(s): ICT01,Pembrolizumab
Therapeutic Area: Oncology Product Name: ICT01
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2022
Details:
The proceeds will be used to support the Phase IIa expansion arms of EVICTION in solid tumors and hematologic cancers, and completion of placebo-controlled clinical trials evaluating ImCheck’s lead candidate ICT01 in combination with a PD-1 inhibitor for multiple solid tumors.
Lead Product(s): ICT01,Pembrolizumab
Therapeutic Area: Oncology Product Name: ICT01
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Earlybird
Deal Size: $103.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing June 13, 2022
Details:
Clinical responses achieved with low doses of ICT01 in combination with pembrolizumab in solid tumor patients who previously failed checkpoint-inhibitor therapy support the complementary mechanisms of action with potential for anti-tumor activity.
Lead Product(s): ICT01,Pembrolizumab
Therapeutic Area: Oncology Product Name: ICT01
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Presented results demonstrating ICT01 plus pembrolizumab induced anti-tumor responses in patients with a range of solid tumors. 5 of 8 patients achieved disease control at 8 weeks and beyond according to RECIST1.1, including two partial responses at week 16 and beyond.
Lead Product(s): Humanized anti-Butyrophilin 3A Monoclonal Antibody,Pembrolizumab
Therapeutic Area: Oncology Product Name: ICT01
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2021
Details:
CT01 is a fully-humanized anti-BTN3A monoclonal antibody designed to selectively activate gamma 9 delta 2 (Vγ9Vδ2) T cells through all three isoforms of BTN3A (1/2/3). CT01 has been shown to have anti-tumor activity against a range of cancers.
Lead Product(s): Humanized anti-Butyrophilin 3A Monoclonal Antibody,Pembrolizumab
Therapeutic Area: Oncology Product Name: ICT01
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2021
Details:
ICT01 is a humanized, anti-BTN3A (CD277) monoclonal antibody that selectively activates γ9δ2 T cells. Monotherapy and combination of ICT01 and pembrolizumab, showed antitumor immune response against bladder cancer, metastatic melanoma and non-small cell lung cancer.
Lead Product(s): Humanized anti-Butyrophilin 3A Monoclonal Antibody,Pembrolizumab
Therapeutic Area: Oncology Product Name: ICT01
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021
Details:
THOR-707, a precisely PEGylated, engineered version of IL-2 built on Sanofi’s Synthorin™ technology platform, is being studied in a trial of adults with advanced or metastatic solid tumors.
Lead Product(s): THOR-707,Pembrolizumab
Therapeutic Area: Oncology Product Name: THOR-707
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Synthorx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2021
Details:
ICT01 activates γ9δ2 T cells that rapidly migrate out of the circulation and secrete IFNγ and TNFα leading to an expanded immune system activation.
Lead Product(s): Humanized anti-Butyrophilin 3A monoclonal antibody,Pembrolizumab
Therapeutic Area: Oncology Product Name: ICT01
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2021
Details:
The data from the first cohort of six solid tumor cancer patients treated with ICT01 monotherapy demonstrated dose-dependent and specific γ9δ2 T cell activation and trafficking out of the circulation without dose-limiting toxicities or related serious adverse events.
Lead Product(s): ICT01
Therapeutic Area: Oncology Product Name: ICT01
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
